In addition to a wide range of case reports, reviews, and small series, here are summaries of recently published HAE-related scientific papers. The source used is the National Library of Medicine (NLM) data search, undertaken on 24 March 2026.

The International/Canadian hereditary angioedema guideline
Betschel S, et al
The authors present an update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline, which builds on international guidelines and was developed through collaboration between Canadian and international HAE experts and patient groups. Specific updates include recommendations on HAE during breastfeeding and a dedicated section on shared decision-making. The authors note that HAE care in Canada lags behind that in comparable nations.
(Allergy, Asthma & Clinical Immunology, January 2026)

Updates in hereditary angioedema and chronic spontaneous urticaria
Gandhi RS, et al
This review summarizes recent advances in the pathophysiology of HAE and how this new knowledge has been crucial in the development of targeted and precision therapies.
(Journal of Allergy and Clinical Immunology, February 2026)

Updates on the current and evolving treatment for hereditary angioedema
Busse PJ, et al
The authors review the expanding landscape of current and potential future treatments for HAE.
(Journal of Allergy and Clinical Immunology: In Practice, February 2026)

International guideline on the diagnosis and management of pediatric patients with hereditary angioedema
Farkas H, et al
A multi-national group of HAE clinical experts and advocacy leaders has developed specific guidance on the management of HAE in children. The authors believe that these guidelines, which take account of the unique challenges of HAE in young people, will ensure early diagnosis and promote more effective therapy.
(Allergy, January 2026)

Emerging role of plasma kallikrein inhibitors in preventing hereditary angioedema flares in pregnancy
Mustafa N, et al
The authors investigate the potential use of the HAE medicine navenibart as a therapeutic option to prevent attacks during pregnancy. They conclude that while there are potential advantages of navenibart, these should be considered only during a shared decision-making framework, and that further research is needed to establish safety and the appropriate role of this and similar medicines in pregnancy.
(Annals of Medicine and Surgery (London), January 2026)

Garadacimab-gxii a novel prophylactic treatment for hereditary angioedema: A drug review
Schindel KM, et al
The authors review the clinical data supporting the use of garadacimab to prevent HAE attacks. They conclude that garadacimab reduces the frequency of HAE attacks, with a safety profile comparable to that of existing prophylaxis treatments. They believe its mode of action offers an alternative approach to HAE management.
(Annals of Pharmacology, January 2026)

CRISPR in medicine: A systematic review of clinical trials and therapeutic applications
Rahmanian M, et al
The authors examine current uses of the gene-editing technology CRISPR. They identify that the technique has demonstrated potential in HAE and that further studies will enable conclusions on efficacy and safety.
(Human Gene Therapy, December 2025)

Recent advances in factor XII(a) inhibitors: An updated patent landscape (2020-present)
Kalinin DV
The author provides an expert opinion on the use of Factor XII(a) inhibitors, showing that to date, these are only being used in very early preclinical experiments but have potential in HAE, along with other conditions. They indicate that progress will likely accelerate, leading to potential medicines that can be tested in clinical trials.
(Expert Opinion on Therapeutic Patents, January 2026)

The power of a pill: Ekterly (sebetralstat): first oral on-demand therapy for hereditary angioedema-a paradigm shift in treatment
Bukhair SMR and Rashidi R
The authors report on the recent FDA approval of the new medicine for HAE, sebetralstat. The authors conclude that the medicine, being an oral therapy, offers advantages for patients and for the treatment of the condition by offering greater control.
(Annals of Medicine and Surgery, January 2026)

A treat-to-target approach in hereditary angioedema: Expert consensus from a European committee
Cancian M, et al
The authors report on the use of a treat-to-target approach to support more consistent use of the currently available WAO/EAACI guidelines for the management of HAE. They believe this is important because it would provide a clearer path towards the normalization of life, which remains the goal of best-practice guidelines. The treat-to-target approach uses a visual framework to help patients start long-term prophylaxis and set appropriate individualized treatment goals. The authors conclude that setting these individualized targets, along with shared decision-making and regular monitoring, promotes more consistency of care and improved outcomes for patients.
(Frontiers in Immunology, February 2026)

Functional physiological, psychological, and biochemical reactivity to socially evaluated cold pressor test in hereditary angioedema patients (FRoSEn)
De Maria B, et al
The paper reports on work to better understand the stress response among people with HAE. The authors used a cold-water-based test (proven to reliably induce acute stress) to understand how people with HAE respond to stressful situations. They conclude that people with HAE show higher levels of perceived stress than those without the condition. The authors feel this may indicate a link between a person’s psychological response and the inflammatory response in HAE.
(Frontiers in Immunology, January 2026)

Population pharmacokinetic/pharmacodynamic modeling of donidalorsen, an antisense oligonucleotide in development for prophylaxis of hereditary angioedema
Diep JK, et al
The authors report on scientific studies examining how infrequently people with HAE may need to take the potential new medicine donidalorsen. The authors found that there is little difference between monthly dosing and taking the medicine every four weeks, and that the same is true for every eight weeks instead of every two months. The authors believe this may make dosing more convenient for patients.
(CPT: Pharmacometrics and Systems Pharmacology, February 2026)

Assessing patient-reported outcomes in acute attacks of hereditary angioedema: Insights from a mixed methods study of participants receiving standard-of-care treatments in a real-world setting
Mendivil J, et al
The authors used patient-reported outcome (PRO) tools to understand better the patient experience of an HAE attack and what would constitute a meaningful improvement, to support future clinical trials of therapies.
(Clinical Reviews in Allergy and Immunology, March 2026)

Advances in hereditary angioedema in the modern treatment era in China: A focus on diagnosis, treatment, and prognosis
Ye Zhao, Duowu Zou
This review examined the available medical literature on the management of HAE in China. The authors reviewed 92 articles before concluding that therapies such as lanadelumab and icatibant are effective in reducing the frequency of HAE attacks and providing rapid symptom relief in Chinese patients with HAE. They suggest further research is needed to address gaps in the evidence in the Chinese population.
(Orphanet Journal of Rare Diseases, March 2026)

Sebetralstat: FDA approves first oral on-demand therapy for hereditary angioedema
Bibi L, et al
The authors highlight the recent FDA approval of sebetralstat. They indicate that although HAE requires quick and effective treatment, existing options can carry downsides. They indicate that effective on-demand oral treatment is welcome, and that additional research to understand the medicine’s safety and use in specific populations will be necessary to draw conclusions about its long-term use in managing HAE.
(Irish Journal of Medical Science, November 2025)

Donidalorsen for long-term prophylaxis of hereditary angioedema attacks: Results from the OASISplus open-label extension cohort at Year 1
Lumry WR, et al
The authors report on a clinical trial extension in which HAE patients continued taking a potential new medicine to prevent attacks. They report on data from 83 patients followed for one year. The study indicated that the average attack rate dropped by 94% compared to before the trial started. A quarter of patients reported a treatment-related side effect, none of which were serious, and the most common were reactions at the site of infection. The authors conclude that donidalorsen showed sustained reductions in HAE attack rate, improvements in quality of life, and an acceptable safety profile after one year of treatment.
(Journal of Asthma and Allergy, February 2026)

A phase 1 randomized study: Garadacimab pharmacokinetics, safety, and tolerability after administration via autoinjector/pre-filled pen versus pre-filled syringe in healthy participants
Glassman F, et al
The authors conducted a trial in healthy volunteers that compared the safety and rate of body absorption of garadacimab when using a new auto-injector/pre-filled pen (AI/PFP) or an existing pre-filled syringe. The authors conclude that the AI/PFP had a consistent safety and tolerability profile, similar to that of the existing pre-filled syringe, providing at-home convenience for patients and physicians.
(The Journal of Clinical Pharmacology, January 2026)

Hereditary angioedema
Regis J, et al
In this review, the authors examine in detail the existing evidence on the underlying causes of HAE, the diagnosis, and current management, to support better care for patients.
(Cardiology in Review, March 2026)

A comprehensive assessment of health-related quality of life in hereditary angioedema as a patient-centered approach
Gungoren EY, et al
This research study focused on the impact of HAE on patients’ quality of life and explored how the location and frequency of attacks may affect how people feel about their lives. Their research concluded that abdominal attacks significantly affected how well people felt they could function in everyday life. In contrast, facial and throat attacks impacted people’s mood and fears. The authors conclude that more personalized treatment strategies could ease the burden of HAE for patients and their families.
(International Archives of Allergy and Immunology, January 2026)

Algorithms in allergy: Hereditary angioedema
Bork K, et al
The authors present an algorithm designed to support clinical decision-making in diagnosing HAE, especially regarding so-called ‘masqueraders’, conditions that may mimic some of its features.
(Allergy, February 2026)

Rethinking the management of hereditary angioedema
Busse P, et al
The authors asked people in the US living with HAE about their lives and how the condition leads them to make changes in their daily lives. They conclude that doctors should, in addition to asking about attacks, also speak to patients about the psychosocial, mental, logistical, and financial burden of lifelong management of HAE.
(Allergy and Asthma Proceedings, March 2026)

Epidemiological and clinical characteristics of hereditary angioedema in the Baltic states
Kurjane N, et al
This study looked at various aspects of HAE in the Baltic states of Estonia, Latvia, and Lithuania. The authors found considerable variation in HAE prevalence, diagnosis, and treatment across countries. Estonia was considered to show best practice, with a median delay to diagnosis of 9.5 years, whereas in Latvia the delay was on average 24 years. The authors suggest that greater regional collaboration and standardized care protocols are urgently needed.
(Frontiers in Immunology, February 2026)

Mast cell mediators in hereditary angioedema
Horváth HR, et al
The authors note that HAE can be hard to differentiate from conditions where mast cells are activated, such as allergic reactions, but that recent research has indicated that people with HAE also report higher than normal rates of mast cell-mediated diseases. The research found that HAE patients had higher levels of a marker enzyme than those in the control group, but these levels did not change during attacks. The authors conclude that these findings indicate that, in some HAE patients, mast cells may be activated, perhaps leading to bradykinin-independent swelling.
(Orphanet Journal of Rare Diseases, March 2026)

Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder
Espada AR, et al
The authors followed up on the initial thinking that the lack of C1-inhibitor does not account for an increased risk of thrombosis in people with HAE. Their research looked at a very large sample of HAE patient genetic data to find that issues with the SERPING1 gene were associated with increased risk of blood clots in the veins, stroke, and a trend towards heart attacks.
(Bloody Advances, February 2026)

Association of muscle instability and long-term prophylaxis in hereditary angioedema
Hollers E, et al
The authors demonstrate that in HAE caused by C1 inhibitor deficiency or dysfunction, levels of an enzyme called creatinine kinase were elevated, indicating that these forms of HAE may negatively impact muscles in the body. The authors suggest that long-term prophylaxis may address these issues and improve weakness and fatigue, which are common in people with HAE.
(World Allergy Organization Journal, March 2026)

Diagnosis and management of pediatric and adolescent hereditary angioedema: A clinical yardstick
MacGinnitie A, et al
The authors recognize that there is now a wide range of treatments for HAE, and that for some patients and clinicians, this can be very confusing. They therefore suggest some simple guidance for managing pediatric and adolescent HAE.
(Annals of Allergy, Asthma and Immunology, March 2026)

Investigation of sexual life and sleep quality in patients with hereditary angioedema
Aykan FS, et al
This research study investigated the sexual function, sleep quality, and related issues in people with HAE. The authors found that sexual life and sleep quality are more impacted than previously understood, and that doctors should ask about these aspects to better understand a patient’s disease control.
(Allergologia et Immunopathia, March 2026)

Unearthing hereditary angioedema in India—Epidemiology from Chandigarh and Reasi, India
Jindal AK, Barman P, Basu S, et al
This research letter provides details on the first study to explore the incidence and distribution of HAE in India. The authors conclude that it is important to develop national registries for HAE to understand gaps in care for patients and to address clinician knowledge gaps.
(Clinical and Experimental Allergy, March 2026

Burden of hereditary angioedema: Results from a multinational survey of caregivers for adult and pediatric patients
Watt M, et al
The authors investigated the impact of HAE on the lives of those caring for someone with the condition. They asked people across Europe and South America to complete a questionnaire to assess their quality of life. They conclude that being an HAE caregiver is very demanding on people’s time, and it also negatively impacts their quality of life, especially their emotional wellbeing.
(Orphanet Journal of Rare Diseases, February 2026)

Ecological momentary assessments for patients with hereditary angioedema: a feasibility and acceptability controlled study
Parati M, et al
This research aimed to gain a better understanding of how people with HAE feel about their condition and their lives by using more immediate quality-of-life data. They used Ecological Momentary Assessment (EMA) tools, such as emails, text messages, and mobile apps, to collect data on people’s lives, including their behavior and psychological state. In this proof-of-concept research, the authors concluded that EMA is a highly feasible and acceptable method for monitoring the impact of HAE and could be used more in clinical settings.
(Frontiers in Digital Health, January 2026)

Achieving a normal life in hereditary angioedema: Quality of life and treatment gaps among German HAE patients
Magerl M, et al
This study examined how quality of life changes for people with HAE when they are attack-free. By asking a range of German HAE patients about their lives, the authors were able to conclude that even a very low number of attacks has a meaningful negative impact on HAE. They suggest that these findings reinforce the importance of working towards complete control of HAE.
(Allergologie Select, February 2026)

Clinical features of hereditary angioedema involving the gastrointestinal tract: A retrospective analysis
Haiyuan M, et al
This study examined the physical aspects of gastrointestinal HAE swelling attacks to improve diagnosis and treatment. The study indicated that the most common symptoms were pain, nausea, and diarrhea. The authors conclude that there are clear biomarkers of gastrointestinal attacks, and that lanadelumab and icatibant demonstrated efficacy in treatment.
(World Allergy Organization Journal, February 2026)

Global research trends in hereditary angioedema, 1972-2023: Bibliometric analysis of productivity, collaboration, and thematic evolution
Mak HWF, et al
This study looked at the breadth and history of HAE research. The authors found that the volume of HAE research is increasing rapidly. Additionally, this research base is becoming more collaborative and diverse, but more support is needed to increase participation from Africa, the eastern Mediterranean, and Southeast Asia.
(World Allergy Organization Journal, March 2026)

Eosinophilic inflammation in hereditary angioedema: a single-center real-world retrospective chart review study
Boch K, et al
This study demonstrates that people with HAE show signs of eosinophil activation, a marker of a previously unrecognized inflammatory process beyond the bradykinin-driven swelling attacks. The authors believe this may mean people with HAE have other conditions at the same time.
(Frontiers in Immunology, February 2026)

Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema
Olson C, et al
This research aimed to understand what people with HAE think about long-term prophylaxis, especially treatment preferences and willingness to switch. The authors found that efficacy was the most important driver of patient preference.
(Annals of Allergy, Asthma and Immunology, March 2026)

Developing a patient journey map to improve care and experience in Chinese patients with hereditary angioedema
Wang Y, et al
The authors worked with patients to better understand the path to diagnosis for Chinese people with HAE. They conclude that the average time to diagnosis is 16 years, and eight out of ten patients report a misdiagnosis. They call for more standardized diagnostic pathways and support beyond treatment, including psychosocial and financial support.
(World Allergy Organization Journal, February 2026)

Classification of angioedema types using decision tree modeling
Aulenbacher F, et al
The authors used machine learning (a form of artificial intelligence or AI) to improve the differential diagnosis of angioedema. The authors found that their machine learning tool was accurate in diagnosing HAE due to C1 inhibitor deficiency in 94% of cases.
(Frontiers in Immunology, January 2026)

Is hereditary angioedema associated with deficits in emotion regulation? A quantitative study in adult patients
Duprez C, et al
The authors found that people with HAE can have difficulties with their emotions as a result of their condition. They found that this may lead to more depression, and it is therefore important to support HAE patients with their mental health.
(Orphanet Journal of Rare Diseases, February 2026)

Clinical and genetic study in factor XII hereditary angioedema in a population from Southern Spain
Mera T, et al
The authors examined the genetic background of HAE-affected individuals and presented this data to support future research.
(Annals of Allergy, Asthma and Immunology, March 2026)

The patient experience of hereditary angioedema: Findings from a racially diverse sample of adult patients
Broderick L, et al
This study spoke directly to a racially diverse population of people with HAE to understand the breadth of patient experience. The authors concluded that the experience of this group was similar to that reported in existing research among predominantly white populations.
(Orphanet Journal of Rare Diseases, February 2026)

Elevated serum zonulin is associated with high attack frequency in hereditary angioedema: providing insight into the gut-angioedema axis
Kural RF, et al
This research examined the potential role of fluid leakage from the gut lining and HAE by measuring the levels of a protein called zonulin. The authors found what they believe may be evidence that elevated zonulin levels in people with HAE may indicate a higher disease burden.
(Orphanet Journal of Rare Diseases, February 2026)

Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: A subanalysis of the EMPOWER study
Betschel SD, et al
This study looked at the effectiveness and safety of lanadelumab in patients with HAE in Canada. They found both were consistent with the broader populations in which the medicine was trialed. The authors conclude that these data support the use of the product as first-line prophylaxis in Canada.
(Allergy, Asthma and Clinical Immunology, January 2026)

Completion of the icatibant outcome survey and what we learned
Bouillet L, et al
In a research letter, the authors present data from a long-term study into the effectiveness of icatibant. They suggest that these data, spanning 15 years, demonstrate that icatibant is effective in HAE, and that no new side effects or safety signals have been identified over that time.
(Clinical and Experimental Allergy, March 2026)

Switching long-term prophylaxis to donidalorsen for hereditary angioedema: 1-Year OASISplus results
Riedl MA, et al
This study tracked what happened in patients who switched from an existing long-term prophylaxis to treatment to the new treatment donidalorsen. The authors conclude that in HAE patients who switched, donidalorsen provided improved control of HAE attacks, improved quality of life, and only mild to moderate side effects.
(Allergy, March 2026)

Impact of oral sebetralstat on anxiety associated with hereditary angioedema attacks
Craig T, et al
This study looked at levels of anxiety related to HAE and the condition’s treatment. The results of the study, which was part of wider research into the new medicine for HAE called sebetralstat, found that moderate to extreme anxiety was common in HAE attacks, but that levels of anxiety were lower in patients treated with sebetralstat compared to placebo.
(Clinical and Experimental Allergy, March 2026)

Comparison of clinical characteristics between hereditary angioedema patients aged 65 years and older and those under 65: A perspective on elderly patients
Tuncay G, et al
The authors examined differences between HAE in patients aged over 65 and those who were younger. They found that the characteristics of the disease were similar regardless of the patient’s age; however, there were variances in treatment. Older patients were more likely to use short-term prophylaxis and less likely to have HAE control in the previous three months.
(Life, January 2026)

Patient preferences for long-term prophylactic treatment in hereditary angioedema: A discrete-choice experiment
Villa KF, et al
This research asked patients about their preferences for HAE treatment. The authors found that the most important feature of treatment is a reduction in attack frequency. Similar proportions of patients also responded that they would prefer reduced gastrointestinal side effects of treatment, and also an oral therapy.
(The Patient, January 2026)

Physiological evaluation of the emotional regulation of patients with hereditary angioedema
Sparrow L, et al
This research used physical measurements of people’s stress levels to better understand the impact of HAE. The authors compared patients with HAE to others with an unrelated illness. The authors conclude that there was no difference between patient groups.
(BioPsychoSocial Medicine, January 2026)

Patient-reported disease burden and health care utilization of HAE-nl-C1INH: insights from a real-world survey
Jones D, et al
This study aimed to compare the characteristics of HAE resulting from C1 deficiency or dysfunction with those of patients with HAE with normal C1. The authors conclude that patients with HAE with normal C1 report a worse disease burden than other forms of HAE.
(Clinical and Experimental Medicine, January 2026)

An open-label Phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema
Banerji A, et al
This early study examined the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of navenibart, which is a potential new long-acting therapy for HAE. The results allow the authors to conclude that navenibart is well-tolerated and substantially reduces HAE attacks. The evidence also suggests that twice or four times a year dosing may be possible.
(Journal of Allergy and Clinical Immunology, March 2026)

An international Delphi study on barriers to on-demand treatment of hereditary angioedema attacks
Banerji A, et al
This expert group worked to establish consensus on the use of on-demand treatment for HAE. The experts agreed that there are obstacles to early treatment, including the need to recognize an attack and the requirement for injectable treatment. The authors conclude that accessible and convenient on-demand treatments for HAE attacks remain vital.
(Clinical and Translational Allergy, March 2026)

Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world
Davis-Lorton M, et al
This study evaluated HAE attack rates before and after treatment with berotralstat. The authors concluded that berotralstat use led to significant and sustained reductions in HAE attack rate, regardless of baseline attack rate.
(Allergy, Asthma and Clinical Immunology, January 2026)

Prevalence, clinical characteristics and the burden of disease of the Croatian adult patients with HAE: nationwide survey analysis
Barešić M, et al
This research demonstrated that efforts to raise awareness and improve the care of HAE in Croatia led to a higher observed prevalence in the country. This was as a result of the work of a dedicated patient advocacy organization and a well-developed network of national HAE experts.
(European Annals of Allergy and Clinical Immunology, March 2026)

Donidalorsen for hereditary angioedema: Long-term results from a 4-year phase 2 open-label extension study
Manning WE, et al
This small-scale study amongst 14 patients with HAE with C1-inhibitor deficiency found that over a prolonged period (4 years), treatment with donidalorsen led to sustained reductions in HAE attack rates, while side effects were considered acceptable.
(Annals of Asthma, Allergy and Immunology, March 2026)

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis
Davis-Lorton M, et al
This study aimed to describe the real-world quality of life and related outcomes of patients with HAE who received lanadelumab versus other long-term prophylaxis. In conclusion, the results showed that clinicians reported a higher proportion of HAE patients without chronic pain or fatigue when treated with lanadelumab than with other long-term prophylaxis regimens.
(Allergy and Asthma Proceedings, March 2026)

Behavioral withdrawal during an acute stress test as a marker of psychobiological vulnerability in hereditary angioedema
Ranucci L, et al
As HAE is believed to be sensitive to stress, leading to attacks, this study aimed to characterize the ways people with HAE respond to stressful situations. The conclusion was that some patients with HAE may have a greater psychological and physical response.
(Frontiers in Immunology, March 2026)

Management of pregnancy, delivery and breast-feeding in hereditary angioedema: An analysis of 15 pregnancies with conventional treatment approaches and a case of lanadelumab use
Casanova M, et al
This study followed the pregnancies of several women with HAE. The authors found that HAE symptoms can vary widely during pregnancy, underscoring the importance of flexible, personalized treatment plans.
(Orphanet Journal of Rare Diseases, February 2026)

Bradykinin reduces wound healing in human umbilical vein endothelial cells via downregulation of vascular endothelial growth factor A
Dimitrova N, et al
This research examined the role of bradykinin in wound healing to determine whether it affects HAE attacks. The authors conclude that bradykinin impairs wound healing, and this may contribute to HAE attacks.
(Journal of Inflammation, January 2026)

Lanadelumab’s enduring effectiveness and safety in the management of hereditary angioedema for patients from Puerto Rico: Data from EMPOWER
Zaragoza-Urdaz RH, et al
This research data supports the clinical benefits and safety of treatment using lanadelumab to prevent HAE attacks in patients in Puerto Rico.
(Immunology and Allergy, March 2026)

Human plasma-derived C1 inhibitor for short-term prophylaxis in hereditary angioedema with normal C1 inhibitor
De Melo Maricondi PCC, et al
This research established that short-term prophylaxis with plasma-derived C1 inhibitor in patients with HAE with normal C1 inhibitor can reduce the risk of post-procedure attacks. The authors conclude that the efficacy in preventing attacks in patients with HAE-FXII was higher than in those with HAE of unknown genetic type.
(Clinical and Experimental Allergy, January 2026)

National audit of long-term real-world outcomes of berotralstat use in UK patients with hereditary angioedema
Elbashir H, et al
This study, which the authors suggest is the most extensive real-world evaluation of berotralstat in the UK, demonstrates that berotralstat is effective in reducing attack frequency and improving disease control.
(Allergy, March 2026)

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): Primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial
Aygören-Pürsün E, et al
These authors set out to evaluate an oral HAE medicine called deucrictibant as a potential treatment to prevent attacks. Their research indicates that it could be a therapeutic approach to prevent HAE attacks.
(Lancet Haemotology, March 2026)

Long-term prophylaxis with lanadelumab in patients with angioedema due to C1 inhibitor deficiency: A real-life study in Spain
De Agrela-Mendes I, et al
In this research letter, the authors conclude that their work has confirmed that lanadelumab is a clinically effective treatment to prevent HAE attacks in HAE due to C1 deficiency or dysfunction, and in acquired angioedema.
(Journal of Investigational Allergology and Clinical Immunology, February 2026)

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): A randomised, double-blind, placebo-controlled, phase 2 trial
Maurer M, et al
The authors examined the safety and efficacy of oral deucrictibant. They found that use of this potential new medicine significantly reduced the severity of HAE attacks compared with placebo. They also note that the side-effect profile is similar to that of placebo.
(Lancet Haematology, March 2026)